期刊文献+

丁酸氯维地平的合成工艺 被引量:10

Technological improvement of synthesis for clevidipine butyrate
原文传递
导出
摘要 目的研究适合工业化生产的丁酸氯维地平合成方法。方法采用2,3-二氯苯甲醛、β-氨基巴豆酸甲酯与乙酰乙酸乙酯环化缩合,选择性水解得到4-(2,3-二氯苯基)-1,4-二氢-2,6-二甲基-3,5-吡啶二羧酸单甲酯钾盐,再同丁酸氯甲酯反应得到丁酸氯维地平。结果该合成工艺的丁酸氯维地平总收率为48%。结论该工艺稳定,操作简单,适合工业化生产丁酸氯维地平。 Objective To investigate the industrialization method for clevidipine butyrate.Methods Clevidipine butyrate was synthesized after several processes,including cyclocondation of 2,3-dichlorobenzalde-hyde,methyl β-aminobutenate and ethyl acetoacetate,selective hydrolysis through which 4-(2,3-dichloro-pheny1)-1,4-dihydro-2,6-dimethy-3,5-pyridinedicarboxylic acid monomethyl ester potassium salt was obtained,and reaction with chloromethy butyrate.Results The total yeild rate of clevidipine butyrate was 48%.Conclusion This method was simple and reproducible,and this synthesis route is suitable for the commercial production of clevidipine butyrate.
出处 《现代药物与临床》 CAS 2010年第6期445-447,共3页 Drugs & Clinic
关键词 丁酸氯维地平 短效钙通道拮抗剂 化学合成:工艺改进 clevidipine butyrate short-action calium channel antagonist chemical synthesis, improvementof technology
  • 相关文献

参考文献9

  • 1FDA. FDA approval letter [EB/OL]. [2008-08-10]. http//: www. fda.gov/cder/foi/applett er/2008/022156s000 ltr.pdf.
  • 2高辉,钟静芬,时惠麟.丁酸氯维地平合成路线图解[J].中国医药工业杂志,2009,40(10):791-793. 被引量:14
  • 3Andersson K H, Nordlander M, Westerlund R C. Preparation of short-acting 2,6-dimethyl-4-phenyl- 1,4-dihydropyridine-3,5- dicarboxylate calcium antagonist antihypertensives: WO,9512578[P]. 1995-05-11.
  • 4Mattson A, Svensson C, Thronblom K, et al. Manufacturing process: US, 6350887 [P]. 2002-02-26.
  • 5Sorberala L A, Castaner J. Clevidipine:treatment of hypertension Calcium channel blocker [J]. Durgs Future, 2004, 29 (2): 105-111.
  • 6Antoncic L, Jazbec I, Kocjan D, et al. Process for the preparation of 2-(N-benzyI-N-methylamino)-ethylmethyl-2,6-dimethyl-4- (mnitropheyl)- 1,4-dihydropydrine-3,5-dicarboxylate and its hydrochloride salt: US, 4769465 [P]. 1988-09-06.
  • 7Suh J J, Hong Y H. Synthesis of 1,4-dihydropydrine carboxylate acids (II)[J]. YakhakHoechi, 1989, 33 (4): 219-225.
  • 8Desai R, Aguilar D A, Aslam M, et al. Process to prepare dihydroprydine and derivatives thereof: WO, 9724326 [P]. 1997-07-10.
  • 9Matteson A, Svensson C. New manufacturing process: EP, 1133473 [P]. 2001-09-19.

二级参考文献10

  • 1US FDA, FDA approval letter [EB/OL]. [2008-08-10]. http://www.fda.gov/cder/foi/appletter/2008/022156s0001tr. pdf.
  • 2Varon J. Treatment of acute severe hypertension: current and newer agents [J]. Drugs, 2008, 68 (3) : 283-297.
  • 3Andersson KH, Nordlander M, Westerlund RC. Preparation of short-acting 2,6-dimethyl-4-phenyl-l,4-dihydropyridine- 3,5-dicarboxylate calcium antagonist antihypertensives: WO, 9512578 [P]. 1995-05-11. (CA 1995, 123: 313768).
  • 4Kosugi Y, Hori M, Nagasaka T. Synthesis of optically pure 1,4-dihydropyridine derivatives by means of diastereoisomeric separation of the hantzsch intermediates bearing (R)-l-phenylethylamino group [J]. Heterocycles, 1994, 39 (2): 591-602.
  • 5Mattson A, Svensson C, Thornblom K, et al. Manufacture of clevidipine from 4- (2,3-dichlorophenyl) -1,4-dihydro-5- methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylic acid: WO, 2000031035 [P]. 2000-06-02. (CA2000, 133: 6161).
  • 6Che D, Guntoori BR, Murthy KKS. Process to prepare 1,4-dihydropyridine intermediates and derivatives thereof: US, 20040204604 [P]. 2004-10-14.
  • 7Suh JJ, Hong YH. Synthesis of 1,4-dihydropyridine carboxylic acids (II) [J].Yakhak Hoechi, 1989, 33 (4) : 219-225.
  • 8Sorberala LA, Castaner J. Clevidipine: treatment of hypertension calcium channel blocker [J]. Drugs Fut, 2004, 29(2): 105-111.
  • 9Wheeler TN, Kenakin TP. Dihydropyridine vasodilator agents: US, 5100892 [P]. 1992-03-31.
  • 10郑伟,胡春.丁酸氯维地平(Cleviprex)[J].中国药物化学杂志,2009,19(1):79-79. 被引量:4

共引文献13

同被引文献71

引证文献10

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部